Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Flerie Invest


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 19
Average round size
The average size of a deal this fund participated in
Portfolio companies 11
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Key employees Soon

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Genetics

The fund has exact preference in some founders of portfolio startups. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight OxThera, Prokarium. Among the most successful fund investment fields, there are Genetics, Health Care.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Flerie Invest, startups are often financed by SLS Venture, HealthCap, Q-Med. The meaningful sponsors for the fund in investment in the same round are Ysios Capital, Sunstone Life Science Ventures, Riyadh Valley Company. In the next rounds fund is usually obtained by Riyadh Valley Company, Korea Investment Partners, Biotechnology and Biological Sciences Research Council.

The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2016. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Flerie Invest:
Typical Co-investors
Flerie Invest is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Flerie Invest:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Atreides Management, LP Boston, Massachusetts, United States
Bainian Kangcheng China, Ningbo, Zhejiang
Beijing Phoenix Wealth Holding Group -
Connectivity Ventures Fund New York, New York, United States
Global Risk Technologies County Dublin, Dublin, Ireland
HDFC Group -
Highland Creek Partners Canada, Ontario, Toronto
Horizen Ventures Bangalore, India, Karnataka
Humanity United California, San Francisco, United States
IIFL India, Maharashtra, Mumbai
InnoSpace China, Hong Kong, Hong Kong Island
LongLing Capital China, Fujian, Xiamen
M. R. Al Khathlan -
Revolution Ventures District of Columbia, United States, Washington
Shunfeng Photovoltaic Changzhou, China, Zhejiang
Slant Design + Marketing Inc. British Columbia, Canada, Vancouver
Sonae Maia, Porto, Portugal
Talwalkars India, Maharashtra, Mumbai
Welsh Development Agency Cardiff, United Kingdom, Wales
Wright Flyer Live Entertainment Chiba Prefecture, Japan, Tateyama

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$18M07 Sep 2022 Solna, Stockholms Lan, Sweden

XNK Therapeutics

$15M29 Mar 2022 Huddinge, Stockholms Lan, Sweden

Geneos Therapeutics

Health Care
$17M24 Mar 2022 Whitemarsh Township, Pennsylvania, United States


Health Care
$68M07 Feb 2022 Cambridge, England, United Kingdom

Synerkine Pharma

Health Care
$4M16 Dec 2021 Utrecht, Utrecht, Netherlands

Amarna Therapeutics

$4M01 Dec 2021 Leiden, South Holland, Netherlands

EpiEndo Pharmaceuticals

Health Care
$23M18 Aug 2021 Iceland, Iceland

KAHR medical

$46M16 Jun 2021 Jerusalem, Jerusalem District, Israel


Health Care
$21M27 Oct 2020 London, England, United Kingdom
EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPD

– EpiEndo Pharmaceuticals announced the closing of a €20m Series A financing round.
– The round was led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council joining the round.
– The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
– EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in propagating chronic inflammatory diseases in lungs and contributes to vulnerability to infections associated with acute exacerbations of airway diseases.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Flerie Invest?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: